Abstract

Amyloid beta-protein (Abeta), the major component of cerebral plaques associated with Alzheimer disease, is derived from amyloid beta-protein precursor (APP) through sequential proteolytic cleavage involving beta- and gamma-secretase. The intramembrane cleavage of APP by gamma-secretase occurs at two major sites, gamma and epsilon, although the temporal and/or mechanistic relationships between these cleavages remain unknown. In our attempt to address this issue, we uncovered an important regulatory role for the APP luminal juxtamembrane domain. We demonstrated in cell-based assays that domain replacements in this region can greatly reduce secreted Abeta resulting from gamma-cleavage without affecting the epsilon-cleavage product. This Abeta reduction is likely due to impaired proteolysis at the gamma-cleavage site. Further analyses with site-directed mutagenesis identified two juxtamembrane residues, Lys-28 and Ser-26 (Abeta numbering), as the critical determinants for efficient intramembrane proteolysis at the gamma-site. Consistent with the growing evidence that epsilon-cleavage of APP precedes gamma-processing, longer Abeta species derived from the gamma-cleavage-deficient substrates were detected intracellularly. These results indicate that the luminal juxtamembrane region of APP is an important regulatory domain that modulates gamma-secretase-dependent intramembrane proteolysis, particularly in differentiating gamma- and epsilon-cleavages.

Highlights

  • Fragment known as amyloid ␤-protein precursor (APP) intracellular domain (AICD) [6, 7]

  • In the present study we examined the significance of APP luminal juxtamembrane domain in ␥-secretase-mediated proteolysis

  • Cleavage of C99GVP by ␥-secretase releases an A␤-like peptide with the extra LE residues on its N terminus [30] as well as an APP intracellular domain (AICD)-like fragment (AICD-GVP) that can transactivate a luciferase reporter through its GVP domain (Fig. 1A)

Read more

Summary

Differential Regulation of APP Cleavages

⑀-cleavages, a potential mechanism that may be exploitable for developing safe ␥-secretase inhibitors for AD therapy. In the present study we examined the significance of APP luminal juxtamembrane domain in ␥-secretase-mediated proteolysis. Through a series of mutagenesis experiments using a C99-derived substrate that contains a Gal4/VP16 (GVP) signaling domain, we were able to evaluate the effects of juxtamembrane mutations on multiple cleavage events within the same substrate. Similar to the wild type C99, C99-GVP is a functional ␥-secretase substrate cleavable at both ␥- and ⑀-sites. Domain swap as well as point mutations in its luminal juxtamembrane domain led to significant reduction in secreted A␤ without affecting AICD production. The divergent effects of these mutations on ␥- and ⑀-cleavages further support a modulatory role for the APP luminal juxtamembrane domain in cleavage specificity in addition to its known function in substrate recognition and recruitment

EXPERIMENTAL PROCEDURES
RESULTS
None DMSO
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call